H. Jack West, MD: We are entering into a new era. Immunotherapy is moving from very frequently used as a second-line or later treatment to increasingly used as either monotherapy or in combination ...

Angiogenesis inhibitors are potent anticancer drugs thought to lack acquired drug resistance problems because they target the normal endothelial cells of the tumor vasculature. But, in February 22 ...

A recent study published in Engineering has shed light on a novel therapeutic target for improving anti-angiogenic treatment in colorectal cancer (CRC). The research, conducted by an international ...

Should 5-Hydroxytryptamine-3 Receptor Antagonists Be Administered Beyond 24 Hours After Chemotherapy to Prevent Delayed Emesis? Systematic Re-Evaluation of Clinical Evidence and Drug Cost Implications ...

A novel protein regulator of tumor angiogenesis, TMEM230, was recently characterized by researchers to have a role in tumor development and vascularization, with potential as a target for anti-tumor ...

The number of lymph node dissections related to survival of patients with locally advanced esophageal squamous cell carcinoma after neoadjuvant therapy: A single-center study. This is an ASCO Meeting ...

The first oral, broad-spectrum angiogenesis inhibitor, specially formulated through nanotechnology, shows promising anticancer results in mice, report researchers from Children's Hospital Boston.

The aim of anti-angiogenesis therapy is to target the abnormal blood vessels growing into a tumor and cut off the blood supply to a cancerous mass. Yet, without an effective blood flow into a tumor, ...